Coris BioConcept

Ownership

Private

Employees

~35

Therapeutic Areas

Infectious Diseases

Stage

Commercial

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Immunochromatographic test (ICT)Molecular amplification assay (e.g., RT-LAMP)Lateral flow test (COVID‑19 and others)Small molecule substrate-based detection for resistance markers

Coris BioConcept General Information

Coris BioConcept has a broad portfolio of rapid in vitro diagnostic kits based on immunochromatography and molecular amplification. Their tests enable fast identification of viral, bacterial and parasitic pathogens as well as key antibiotic resistance mechanisms. The company’s RESIST range allows rapid detection of carbapenemase-producing bacteria. All products meet CE marking requirements and are distributed in over sixty countries.

Contact Information

Website

https://www.corisbio.com/

Primary Industry

Molecular Diagnostics

Corporate Office

Gembloux, Namur
Belgium

Drug Pipeline

No pipeline data available

For full access to Coris BioConcept's pipeline data

Book a demo

Key Partnerships

Participates in national/international scientific projects including EU FP6/FP7/H2020 collaborations

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Coris BioConcept Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Coris BioConcept's complete valuation and funding history, request access »